Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?

(MedPage Today) -- Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson's disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed.
At 96 weeks, mean Movement Disorder Society...